Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal potential biomarkers and therapeutic targets.

Di Maria Jiang,Bryan Wong,Aaron Richard Hansen,Nazanin Fallah-Rad,Adrian G. Sacher,Tong Zhang,Shamini Selvarajah,Tracy L. Stockley,Philippe L. Bedard,Srikala S. Sridhar

Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal potential biomarkers and therapeutic targets.

2020

Di Maria Jiang
Bryan Wong
Aaron Richard Hansen
Nazanin Fallah-Rad
Adrian G. Sacher
Tong Zhang
Shamini Selvarajah
Tracy L. Stockley
Philippe L. Bedard
Srikala S. Sridhar

198Background: Docetaxel and androgen receptor (AR) targeted agents have become standard options for mCSPC. CGP data is limited in mCSPC, however has the potential to guide treatment selection. We ...

Keywords:

Pathology
Biomarker (medicine)
Prostate cancer
Oncology
Internal medicine
Medicine
Docetaxel
Androgen receptor
genomic profiling
Cancer research
potential biomarkers

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations